Armand Girard - Jan 21, 2022 Form 4 Insider Report for GLYCOMIMETICS INC (GLYC)

Role: SVP, Chief Business Officer
Signature: /s/ Brian F. Leaf, attorney-in-fact
Stock symbol: GLYC
Transactions as of: Jan 21, 2022
Transactions value $: $0
Form type: 4
Date filed: 1/25/2022, 08:02 PM
Next filing: Mar 10, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GLYC	Employee Stock Option (right to buy)	Award	$0	+145K		$0.00	145K	Jan 21, 2022	Common Stock	145K	$1.11	Direct	F1
transaction	GLYC	Employee Stock Option (right to buy)	Award	$0	+47.7K		$0.00	47.7K	Jan 21, 2022	Common Stock	47.7K	$1.11	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the shares underlying this option will vest on January 21, 2023 and the remaining underlying shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date.
F2	50% of the shares underlying this option will vest upon FDA approval of the Issuer's product candidate uproleselan as a treatment for relapsed/refractory acute myeloid leukemia and the remainder will vest upon the first commercial sale of uproleselan in the United States or abroad, subject in each case to the Reporting Person's continued service with the Issuer through the applicable vesting date.

Content

25% of the shares underlying this option will vest on January 21, 2023 and the remaining underlying shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date.

50% of the shares underlying this option will vest upon FDA approval of the Issuer's product candidate uproleselan as a treatment for relapsed/refractory acute myeloid leukemia and the remainder will vest upon the first commercial sale of uproleselan in the United States or abroad, subject in each case to the Reporting Person's continued service with the Issuer through the applicable vesting date.